文献速递泌尿生殖技术与安全PET

PSMA靶向PET示踪剂肝脏背景摄取:系统综述与Meta分析

Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.
PubMed 文献 · Radiol Imaging Cancer · 2026-01-01

本研究系统检索PubMed、Embase、Web of Science和Cochrane截至2025年5月12日的文献,纳入17项研究共1497例患者,比较四种PSMA靶向PET示踪剂的肝脏背景摄取。结果发现不同示踪剂肝脏背景SUV存在差异,可能影响以肝脏活性为参考标准时的PSMA靶向治疗患者筛选。

要点

  • 18F-PSMA-1007肝脏背景摄取最高(12.1),明显高于其他三种示踪剂
  • 以肝脏活性为参考判断PSMA阳性转移灶时,需注意不同示踪剂阈值不同
  • 18F-piflufolastat与68Ga-PSMA-11肝脏背景摄取相近,差异无统计学意义

核心结论

  • 四种PSMA靶向PET示踪剂肝脏背景摄取存在差异,可能影响以肝脏活性为参考标准时的PSMA靶向治疗患者筛选

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Web of Science和Cochrane数据库,时间截至2025年5月12日
  • 纳入17项研究共1497例患者,采用随机效应模型和稳健方差估计进行汇总比较
  • 研究对象为接受四种PSMA靶向PET示踪剂(18F-piflufolastat、68Ga-PSMA-11、18F-flotufolastat、18F-PSMA-1007)检查的患者

关键影像表现/征象

  • 18F-piflufolastat肝脏背景平均SUV为5.0(95% CI: 3.6, 6.3)
  • 68Ga-PSMA-11肝脏背景平均SUV为5.1(95% CI: 4.3, 5.9),与18F-piflufolastat相比P = .579
  • 18F-flotufolastat肝脏背景平均SUV为7.2(95% CI: 6.3, 8.2),与18F-piflufolastat相比P = .005
  • 18F-PSMA-1007肝脏背景平均SUV为12.1(95% CI: 11.4, 12.9),与18F-piflufolastat相比P < .001

诊断标准与关键数值

  • 四种示踪剂肝脏背景平均SUV汇总值:18F-piflufolastat为5.0,68Ga-PSMA-11为5.1,18F-flotufolastat为7.2,18F-PSMA-1007为12.1
  • 以肝脏活性为参考定义PSMA阳性转移灶时,不同示踪剂的参考背景值不同,18F-PSMA-1007的肝脏背景明显更高

临床应用与阅片要点

  • 阅片时应注意所用PSMA示踪剂类型,不同示踪剂肝脏背景活性差异可影响转移灶的视觉判断
  • 以肝脏摄取为背景参考判断病灶是否为PSMA阳性时,18F-PSMA-1007需采用更高的背景阈值
  • 报告PSMA PET结果时建议注明所用示踪剂种类及相应肝脏背景参考水平

局限性

  • 纳入研究数量有限(17项),各示踪剂研究间可能存在方法学异质性
  • 原文未报告纳入研究的偏倚风险评估和效应量异质性统计量

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To perform a systematic review and meta-analysis of liver background uptake across four prostate-specific membrane antigen (PSMA)-targeting PET radiotracers (fluorine 18 [18F]-piflufolastat, gallium 68 [68Ga]-PSMA-11, 18F-flotufolastat, and 18F-PSMA-1007) and evaluate the potential impact on patient selection for PSMA-targeted therapy. Materials and Methods A comprehensive literature search was conducted in PubMed, Embase, Web of Science, and Cochrane through May 12, 2025, to identify human studies reporting quantitative liver background uptake for the four PSMA-targeted PET radiotracers of interest. For each eligible study, liver background uptake was extracted as standardized uptake values (SUVs) and summarized and compared by radiotracer using random effects models with robust variance estimation. Results Among 652 unique records, 17 studies with 1497 total patients met inclusion criteria and reported liver background SUVs. Summary mean liver background SUV was 5.0 (95% CI: 3.6, 6.3) for 18F-piflufolastat, 5.1 (95% CI: 4.3, 5.9) for 68Ga-PSMA-11 (P = .579 compared with 18F-piflufolastat), 7.2 (95% CI: 6.3, 8.2) for 18F-flotufolastat (P = .005), and 12.1 (95% CI: 11.4, 12.9) for 18F-PSMA-1007 (P < .001). Conclusion Liver background uptake differed across PSMA-targeted PET radiotracers and may influence patient eligibility for PSMA-targeted therapy when liver activity is used as a reference for defining PSMA-positive metastatic prostate cancer. Keywords: PET, Genital/Reproductive, Prostate, 68Ga-PSMA-11, 18F-piflufolastat, 18F-flotufolastat, 18F-PSMA-1007, PSMA-targeted PET, PSMA-targeted Therapy Supplemental material is available for this article. © RSNA, 2026.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Ulaner, Parihar, Calais, et al. Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis. Radiol Imaging Cancer. 2026. PMID: 42313080. doi:10.1148/rycan.250732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。